Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.
Vincent J. Picozzi, MD
Advertisement
Articles by Vincent J. Picozzi, MD
Vincent Picozzi, MD, discusses the addition of TFields to gemcitabine and nab-paclitaxel in locally advanced pancreatic ductal adenocarcinoma.
Vincent J. Picozzi Jr, MD, discusses the prognostic value of pathologic response to neoadjuvant chemotherapy in patients with resected pancreatic cancer.
Vincent J. Picozzi, MD, director, Pancreatic Center of Excellence, Virginia Mason Medical Center, discusses the use of SM-88 in pancreatic cancer.
Advertisement
Latest Updated Articles
Dr. Picozzi on the Use of SM-88 in Pancreatic CancerPublished: January 29th 2019 | Updated:
Dr. Picozzi on Prognostic Value of Pathologic Response to Chemo in Pancreatic CancerPublished: April 24th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
5